Skip to main content
Fig. 5 | Clinical Epigenetics

Fig. 5

From: BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocytes from patients with cardiovascular disease and type 2 diabetes

Fig. 5

Genes hyper-sensitive to IFNγ stimulation are inhibited by 25 μM apabetalone (Apa) in DM2 + CVD monocytes. a Hyper-activation of the transcriptional response to IFNγ in monocytes obtained from DM2 + CVD patients (blue squares) compared to control cohort (grey circles). Gene expression changes are presented as means of endogenous control-normalized counts (Nanostring). b MYD88 and CCL7 are IFNγ inducible in DM2 + CVD monocytes only. c IFITM2 is hyper-responsive in control monocytes. d Genes differentially responsive to IFNγ are suppressed by apabetalone. Endogenous control-normalized counts are shown (NanoString). Statistics: 2-Way repeated measures ANOVA followed by Tukey’s multiple comparisons test (within-group comparisons; blue bars and asterisks) or Bonferroni’s test (between-group comparison; black bars and asterisks); *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; ns non-significant. Individual patient data were shown as a mean ± SEM

Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us